Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.71 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8040811 | 0.89 | OPRM1 (0.66) | OPRM1OPRL1OPRD1CHRM4CCR3 | |
| SCHEMBL5193076 | 0.87 | OPRM1 (0.52) | OPRM1OPRL1CCR3DRD2POLB | |
| SCHEMBL8350406 | 0.85 | OPRM1 (0.81) | OPRM1OPRL1OPRD1CHRM4DRD2 | |
| SCHEMBL476404 | 0.83 | OPRM1 (1.00) | OPRM1OPRL1OPRD1CHRM4DRD2 | |
| SCHEMBL13543973 | 0.83 | OPRL1 (0.79) | OPRM1OPRL1OPRD1CHRM4CCR3 | |
| Hydrochloric Acid SCHEMBL2473959 | 0.82 | OPRM1 (0.97) | OPRM1OPRL1OPRD1CHRM4DRD2 | |
| SCHEMBL31567223 | 0.82 | OPRM1 (0.71) | OPRM1OPRL1OPRD1CHRM4CCR3 | |
| SCHEMBL3895012 | 0.81 | OPRM1 (0.83) | OPRM1OPRL1OPRD1CHRM4CCR3 | |
| SCHEMBL6248119 | 0.80 | OPRM1 (0.68) | OPRM1OPRL1 | |
| SCHEMBL373586 | 0.80 | OPRM1 (0.81) | OPRM1OPRL1OPRD1CHRM4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773823-B1 | 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2013-08-21 | — | — | EP | disclosed |
| US-7521449-B2 | 4-arylmorpholin-3-one derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2009-04-21 | — | — | US | disclosed |
| US-20070142349-A1 | 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-06-21 | — | — | US | disclosed |
| EP-1773823-A1 | 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006021654-A1 | 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142349-A1 | 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | ADRB3, ADRA2C, OPRK1 | OPRM1 5/4885OPRL1 9/4885OPRD1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.